We examined the efficacy of using attenuated non-replicating Toxoplasma gondii uracil auxotrophs that can be safely delivered as anticancer immunotherapeutics. This strategy exerted remarkable therapeutic activity in murine models of melanoma and ovarian carcinoma, and holds broad potential for the development of novel, highly effective anticancer vaccines.
Keywords: CD8+ T cells; anticancer vaccines; cancer immunotherapy; non-replicating Toxoplasma gondii; reversing tumor-derived immunosuppression.